Generate QR code
Open Access
Subscription Access
The possibility of surgical treatment of urolithiasis in patients with chronic kidney disease
Sergey V. Popov,
Ruslan H. Huseynov,
Konstantin V. Sivak,
Tatiana A. Lelyavina,
Nikolay S. Bunenkov,
Ahmed H. Beshtoev https://doi.org/10.36485/1561-6274-2025-29-1-35-45
EDN: APELNU
Abstract
The prevalence of urolithiasis, despite the success in its treatment, has been increasing in recent decades. Chronic kidney disease (CKD) is a natural complication of urolithiasis and is therefore also characterized by a tendency to increase in prevalence. This led to our interest in CKD in patients with urolithiasis and approaches to optimizing optimal patient management tactics. The analysis of modern literature sources is carried out, the epidemiological, pathogenetic and clinical aspects of the features of the course of CKD on the background of urolithiasis are considered. Practical recommendations are formulated.
About the Authors
Sergey V. Popov
St. Luke's Clinical Hospital of the St. Petersburg Government Health Committee
Russian Federation
Russian Federation
Sergey V. Popov, MD, PhD, DMedSci, Prof., Honored Doctor of the Russian Federation, Chief Physician,
44, Chugunnaya St., St. Petersburg, 194044.
Phone: +7(812)576-11-08.
Ruslan H. Huseynov
St. Luke's Clinical Hospital of the St. Petersburg Government Health Committee
Russian Federation
Russian Federation
Ruslan H. Huseynov, MD, PhD, Deputy Chief Physician for Scientific Activities,
44, Chugunnaya St., St. Petersburg, 194044.
Phone: +7(812)576-11-08.
Konstantin V. Sivak
St. Luke's Clinical Hospital of the St. Petersburg Government Health Committee
Russian Federation
Russian Federation
Konstantin V. Sivak, MD, PhD, DMedSci, Senior Researcher of the Scientific Department,
44, Chugunnaya St., St. Petersburg, 194044.
Phone: +7(812)576-11-08.
Tatiana A. Lelyavina
V.A. Almazov National Research Medical Center of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Tatiana A. Lelyavina, MD, PhD, DMedSci Leading Researcher,
2, Akkuratova str., St. Petersburg, 198992.
Nikolay S. Bunenkov
St. Luke's Clinical Hospital of the St. Petersburg Government Health Committee
Russian Federation
Russian Federation
Nikolay S. Bunenkov, Researcher of the Scientific Department,
44, Chugunnaya St., St. Petersburg, 194044.
Phone: +7(812)576-11-08.
Ahmed H. Beshtoev
St. Luke's Clinical Hospital of the St. Petersburg Government Health Committee
Russian Federation
Russian Federation
Akhmed Kh. Beshtoev, Researcher,
44, Chugunnaya St., St. Petersburg, 194044.
Phone: +7(812)576-11-08.
References
1. Alhamad T. Nephrology. Subspecialty Consult. Editors Tarek Alhamad, Steven Cheng, Anitha Vijayan. Washington, University in Stlouis, 2021, 485 p. eISBN: 978-1-975113-47-6
2. Johnson RJ, Floege J, Tonelli M. Comprehensive Clinical Nephrology. Seventh Edition. Elsevier, 2024, 1309 p. ISBN: 978-0323-82592-4
3. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis 2021;49(1):27–39
4. Ferraro PM, Unwin R, Bonny O, Gambaro G. Practice patterns of kidney stone management across European and non-European centers: an in-depth investigation from the European Renal Stone Network (ERSN). J Nephrol 2021;34(4):1337–1346. doi: 10.1007/S40620-020-00854-6
5. Brown Robert Stephen. Clinical handbook of nephrology.Elsevier, 2024, 313 p. ISBN: 978-0-323-84787-2
6. Bushinsky DA. Nephrolithiasis. In: Goldman S, ed. GoldmanCecil, Medicine. Elsevier; 2020:776–781
7. Pak YuG, Yagudaev DM, Gallyamov EA. Functional state of the renal parenchyma after various video endosurgical methods of treatment of patients with large and complex stones. Surgical practice 2021;3(44):5–21. (In Russ.) https://doi.org/10.38181/2223-24272021-3-5-21
8. Bespalova ID, Boschenko VS, Koshchavtseva YuI et al. Gender aspects of the development of urolithiasis in patients with metabolic syndrome. Bulletin of Siberian medicine 2021; 20 (4):123–130. (I n Russ.) https://doi.org/10.20538/1682-0363-2021-4-123-130
9. Wilcox CR, Whitehurst LA, Somani BK, Cook P. Kidney stone disease: an update on its management in primary care. Br J Gen Pract 2020;70(693):205–206. doi: 10.3399/BJGP20X709277
10. Terence Kee Yi Shern. The Kidney Book. A Practical Guide on Renal Medicine. Editors: Terence Kee Yi Shern, Jason Choo Chon Jun, Woo Keng Thye. Tan Chieh Suai. World Scientific Publishing, Singapore, 2024, 869 p. ISBN 978-981-12-8422-9 (paperback)
11. Mustafa Arıcı. Management of Chronic Kidney Disease. A Clinician’s Guide. Second Edition. Editor Mustafa Arıcı. Switzerland AG, 2023, 603р. ISBN 978-3-031-42045-0 (eBook) https://doi.org/10.1007/978-3-031-42045-0
12. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet 2021;398(10302):786–802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24. PMID: 34175022
13. Dhondup T, Kittanamongkolchai W, Vaughan LE, Mehta RA, Chhina JK, Enders FT, Rule AD (2018). Risk of ESRD and mortality in kidney and bladder stone formers. American Journal of Kidney Diseases 72(6):790–797. https://doi.org/10.1053/j.ajkd.2018.06.012
14. Schönauer R, Scherer L, Nemitz-Kliemchen M, Hagemann T, Hantmann E, Seidel A, Müller L, Kehr S, Voigt C, Stolzenburg J-U, Halbritter J (2022). Systematic assessment of monogenic etiology in adult-onset kidney stone formers undergoing urological intervention–evidence for genetic pretest probability. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 190C:279–288. https://doi.org/10.1002/ajmg.c.31991
15. Uribarri J. Chronic kidney disease and kidney stones. Curr Opin Nephrol Hypertens 2020 Mar;29(2):237–242. doi: 10.1097/MNH.0000000000000582. PMID:31972597
16. Royuk RV, Yarovoy SK. Chronic kidney disease in patients with recurrent nephrolithiasis and concomitant damage to the cardiovascular system. Bulletin of Urology 2021;9(3):52–61. (In Russ.) doi: 10.21886/2308-6424-2021-9-3-52-613-52-61
17. Scurt FG, Ganz MJ, Herzog C, Bose K, Mertens PR, Chatzikyrkou C. Association of metabolic syndrome and chronic kidney disease. Obesity Reviews 2024;25(1):e13649. doi: 10.1111/obr.13649
18. Reisinger C, Nkeh-Chungag BN, Fredriksen PM, Goswami N. The prevalence of pediatric metabolic syndrome – a critical look on the discrepancies between definitions and its clinical importance. Int J Obes (Lond) 2021;45(1):12–24. doi: 10.1038/s41366-020-00713-1
19. Noubiap JJ, Nansseu JR, Lontchi-Yimagou E et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health 2022;6:158–170
20. Lee TH, Chen JJ, Wu CY, Yang CW, Yang HY. Hyperuricemia and progression of chronic kidney disease: a review from physiology and pathogenesis to the role of urate-lowering therapy. Diagnostics (Basel) 2021;11(9):11. doi: 10.3390/diagnostics11091674
21. Ramaswamy K, Shah O. Metabolic syndrome and nephrolithiasis. Transl Androl Urol 2014;3(3):285–295. doi: 10.3978/j.issn.2223-4683.2014.06.03
22. Royuk RV, Yarovoy SK, Guseva NA et al. Epidemiological aspects of the combination of nephrolithiasis and chronic diseases of the cardiovascular system. Research and practice in medicine 2020; 7(1): 38–47. (In Russ.) doi: 10.17709/2409-2231-2020-7-1-4
23. Goldfarb DS, Avery AR, Beara-Lasic L, Duncan GE, Goldberg J. A twin study of genetic influences on nephrolithiasis in women and men. Kidney International Reports 2019; 4(4), 535–540. https://doi.org/10.1016/j.ekir.2018.11.017
24. Daga A, Majmundar AJ, Braun DA, Gee HY, Lawson JA, Shril S,… Hildebrandt F. Whole exome sequencing frequently detects a monogenic cause in early onset nephrolithiasis and nephrocalcinosis. Kidney International 2018; 93(1): 204–213. https://doi.org/10.1016/j.kint.2017.06.025
25. Cogal AG, Arroyo J, Shah RJ, Reese KJ, Walton BN, Reynolds LM, … Investigators of the Rare Kidney Stone Consortium. Comprehensive genetic analysis reveals complexity of monogenic urinary stone disease. Kidney International Reports 2021;6(11): 2862–2884. https://doi.org/10.1016/j.ekir.2021.08.033
26. Zhao Y, Fang X, He L, Fan Y, Li Y, Xu G, … Geng H. A comparison of the clinical characteristics of pediatric urolithiasis patients with positive and negative molecular diagnoses. World Journal of Urology 2022;40:1211–1216. https://doi.org/10.1007/s00345-022-03934-3
27. Howles SA, Thakker RV. Genetics of kidney stone disease. Nat Rev Urol 2020;17(7):407–421. doi:10.1038/S41585-0200332-X
28. Sun BB, Kurki MI, Foley CN, Mechakra A, Chen CY, Marshall E, Runz H. Genetic associations of protein-coding variants in human disease. Nature 2022;603(7899):95–102. https://doi.org/10.1038/s41586-022-04394-w
29. Chang C-W, Ke H-L, Lee J-I, Lee YC, Jhan JH, Wang HS, …Geng JH. Metabolic syndrome increases the risk of kidney stone disease: A cross-sectional and longitudinal cohort study. Journal of Personalized Medicine 2021; 11(11): 1154. https://doi.org/10.3390/jpm11111154
30. Rahman IA, Nusaly IF, Syahrir S, Nusaly H, Mansyur MA. Association between metabolic syndrome components and the risk of developing nephrolithiasis: A systematic review and bayesian metaanalysis. F1000Res 2021;10:104. https://doi.org/10.12688/f1000research.28346.1
31. Kim SH, Rhee Y, Kim YM et al. Prevalence and complications of nonsurgical hypoparathyroidism in Korea: a nationwide cohort study. PLOS One 2020;15(5):e0232842
32. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int 2021;99(3S):S1–S87. doi: 10.1016/J.KINT.2020.11.003
33. Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO. The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1–84): a retrospective cohort study. Clin Endocrinol (Oxf) 2023;98:496–504. doi: 10.1111/cen.14813
34. Witting C, Langman CB, Assimos D et al. Pathophysiology and treatment of enteric hyperoxaluria. Clin J Am Soc Nephrol 2021;16(3):487–495. doi: 10.2215/CJN.08000520
35. Shee K, Stoller ML. Perspectives in primary hyperoxaluria—historical, current and future clinical interventions. Nat Rev Urol 2022;19(3):137–146. doi: 10.1038/S41585-021-00543-4
36. Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K. Future treatments for hyperoxaluria. Curr Opin Urol 2020;30(2):171. doi: 10.1097/MOU.0000000000000709
37. Alexander RT, Fuster DG, Dimke H. Mechanisms underlying calcium nephrolithiasis. Annu Rev Physiol 2022;84:559–583. doi: 10.1146/ANNUREV-PHYSIOL-052521-121822
38. Runova GE, Pesheva ED, Vastistova AA et al. Hypercalcemia with the development of chronic kidney disease, nephrolithiasis after the introduction of oil solutions into the muscles. Osteoporosis and osteopathies 2023;26(3):33–39. (In Russ.) https://doi.org/10.14341/osteo13141
39. Dhayat NA, Faller N, Bonny O et al. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC Nephrol 2018;19(1):349. doi: 10.1186/s12882-018-1144-6
40. Howles SA, Wiberg A, Goldsworthy M, Bayliss AL, Gluck AK, Ng M, … Furniss D. Genetic variants of calcium and vitamin D metabolism in kidney stone disease. Nature Communications 2019; 10(1):5175. https://doi.org/10.1038/s41467-019-13145-x
41. Irzyniec T, Boryn´ M, Kasztalska J, Nowak-Kapusta Z, Maciejewska-Paszek I, Grochowska-Niedworok E. The effect of an oral sodium phosphate load on parathyroid hormone and fibroblast growth factor 23 secretion in normo- and hypercalciuric stoneforming patients. Clin Nutr 2020;39(12):3804–3812. doi: 10.1016/J.CLNU.2020.04.020
42. Youssef RF, Martin JW, Sakhaee K et al. Rising occurrence of hypocitraturia and hyperoxaluria associated with increasing prevalence of stone disease in calcium kidney stone formers. Scand J Urol 2020;54(5):426–430. doi: 10.1080/21681805.2020.1794955.
43. Tang P-K, Jepson RE, Chang Y-M, Geddes RF, Hopkinson M, Elliott J. Risk factors and implications associated with renal mineralization in chronic kidney disease in cats. J Vet Intern Med 2022;36(2):634–646. doi: 10.1111/jvim.16363
44. Singh P, Harris PC, Sas DJ, Lieske JC. The genetics of kidney stone disease and nephrocalcinosis. Nat Rev Nephrol 2022;18(4):224–240. doi:10.1038/s41581-021-00513-4
45. Khodyreva LA, Starodubova AV, Solovyov VV et al. Urate nephrolithiasis: diagnosis, treatment. Proceedings of the Scientific Research Institute of Healthcare Organization and Medical Management : A collection of scientific papers. Issue 7. Moscow: State Budgetary Institution of the city of Moscow "Scientific Research Institute of Healthcare Organization and Medical Management of the Department of Healthcare of the City of Moscow", 2021:210–225. (In Russ.). EDN CCPHMU
46. Huynh LM, Dianatnejad S, Tofani S et al. Metabolic diagnoses of recurrent stone formers: temporal, geographic and gender differences. Scand J Urol 2020;54(6):456–462. doi: 10.1080/21681805.2020.1840430
47. Rao IR, Bangera A, Nagaraju SP, Shenoy SV, Prabhu RA, Rangaswamy D et al. Chronic kidney disease of unknown aetiology: A comprehensive review of a global public health problem. Trop Med Int Health 2023;28(8):588–600. https://doi.org/10.1111/tmi.13913
48. Moe OW, Xu LHR. Hyperuricosuric calcium urolithiasis. J Nephrol 2018;31(2):189–196. doi: 10.1007/S40620-018-0469-3
49. Adomako E, Moe OW. Uric acid and urate in urolithiasis: the innocent bystander, instigator, and perpetrator. Semin Nephrol 2020;40(6):564–573. doi: 10.1016/j.semnephrol.2020.12.003
50. Zheng WW, Zhou Q, Xue ML, Yu X, Chen JT, Ao L, Wang CD. Association between inflammatory bowel disease, nephrolithiasis, tubulointerstitial nephritis, and chronic kidney disease: A propensity score-matched analysis of US nationwide inpatient sample 2016–2018. J Dig Dis 2023 Nov;24(11):572–583. doi: 10.1111/1751-2980.13233. Epub 2023 Nov 14. PMID: 37823607
51. Eisner BH, Goldfarb DS, Baum MA et al. Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement. J Endourol 2020;34(11):1103–1110. doi: 10.1089/END.2019.0703
52. Moore SL, Cook P, de Coninck V et al. Outcomes and longterm follow-up of patients with cystine stones: a systematic review. Curr Urol Rep 2019;20(6):27. doi: 10.1007/S11934-019-0891-7
53. Nazzal L, Blaser MJ. Does the receipt of antibiotics for common infectious diseases predispose to kidney stones? A cautionary note for all health care practitioners. J Am Soc Nephrol 2018;29(6):1590–1592
54. Tasian GE, Jemielita T, Goldfarb DS et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol 2018;29(6): 1731–1740
55. Santoriello D, Al-Nabulsi M, Reddy A, Salamera J, D’Agati VD, Markowitz GS. Atazanavir-associated crystalline nephropathy. Am J Kidney Dis 2017;70(4):576–580. doi: 10.1053/J.AJKD.2017.02.376
56. Daudon M, Frochot V, Bazin D, Jungers P. Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment. Drugs 2018;78(2):163–201. doi: 10.1007/S40265-017-0853-7
57. Moore CL, Bhargavan-Chatfield M, Shaw MM, Weisenthal K, Kalra MK. Radiation dose reduction in kidney stone CT: a randomized, facility-based intervention. J Am Coll Radiol 2021;18(10):1394–1404. doi: 10.1016/J.JACR.2021.05.004
58. Servais A, Thomas K, Dello Strologo L et al. Cystinuria: clinical practice recommendation. Kidney Int 2021; 99(1):48–58. doi: 10.1016/J.KINT.2020.06.035
59. Abu-Ghanem Y, Kleinmann N, Erlich T, Winkler HZ, Zilberman DE. The impact of dietary modifications and medical management on 24-hour urinary metabolic profiles and the status of renal stone disease in recurrent stone formers. Isr Med Assoc J 2021;23(1):12–16
60. Borisov VV, Shilov EM. Litholytic therapy in the urate nephrolithiasis (clinical lecture). Nephrology (Saint-Petersburg) 2016;20(4): 107–112. (In Russ.)
61. Medina-Escobedo M, Sánchez-Pozos K, GutiérrezSolis AL, Avila-Nava A, González-Rocha L, Lugo R. Recurrence of Nephrolithiasis and Surgical Events Are Associated with Chronic Kidney Disease in Adult Patients. Medicina (Kaunas) 2022 Mar 12;58(3):420. doi: 10.3390/medicina58030420. PMID: 35334596; PMCID:PMC8954899
62. Chuang TZ, Hung HC, Li SF et al. Risk of chronic kidney disease in patients with kidney stones – a nationwide cohort study. BMC Nephrol 2020;21:292–298
63. Kim CH, Chung DY, Rha KH, Lee JY, Lee SH. Effectiveness of percutaneous nephrolithotomy, retrograde intrarenal surgery, and extracorporeal shock wave lithotripsy for treatment of renal stones: a systematic review and meta-analysis. Medicina (Kaunas) 2020;57(1):1–23. doi: 10.3390/MEDICINA57010026
64. Pak YuG, Yagudaev DM. The effect of endovideoscopic surgery in nephrolithiasis on the functional state of the kidneys. Experimental and Clinical Urology 2022;15(1):85–89. (In Russ.) https://doi.org/10.29188/2222-8543-2022-15-1-85-89
65. Popov SV, Huseynov RG, Miloserdov IA, Kisil YuV et al. The effectiveness of remote shock wave lithotripsy of transplanted kidney stones. Hope or disappointment? Bulletin of Transplantology and Artificial Organs 2023; 25(3): 57–63. (In Russ.) doi: 10.15825/1995-1191-2023-3-57-63
66. Tsai SH, Chung HJ, Tseng PT et al. Comparison of the efficacy and safety of shockwave lithotripsy, retrograde intrarenal surgery, percutaneous nephrolithotomy, and minimally invasive percutaneous nephrolithotomy for lower-pole renal stones: a systematic review and network meta-analysis. Medicine (Baltimore) 2020;99(10):e19403. doi: 10.1097/MD.0000000000019403
67. Veser J, Jahrreiss V, Seitz C. Innovations in urolithiasis management. Curr Opin Urol 2021;31(2):130–134. doi: 10.1097/MOU.0000000000000850
68. Ansari FM, Para SA, Wani MS, Bhat AH, Khawaja AR, Malik SA, Mehdi S, Ashraf W, Singh S, Maurya M, Mushtaq A. MiniPCNL – a boon for CKD patients with nephrolithiasis. Arab J Urol 2023 Dec 26;22(2):115–120. doi: 10.1080/20905998.2023.2295041. PMID: 38481409; PMCID: PMC10929665
69. Shah TT, Gao C, Peters M et al. British Urology Researchers in Surgical Training (BURST) Collaborative MIMIC Study Group. Factors associated with spontaneous stone passage in a contemporary cohort of patients presenting with acute ureteric colic: results from the Multi-centre cohort study evaluating the role of Inflammatory Markers in patients presenting with acute ureteric Colic (MIMIC) study. BJU Int 2019;124(3):504–513
70. Turk C (Chair), Neisius A, Petrik A et al. European Association of Urology Guidelines on Urolithiasis; 2020. www.uroweb.org/guideline/urolithiasis
71. Chukhlovin AB, Emanuel YuV, Napalkova OV, Landa SV, Emanuel VL. Role of local infections in development of urolithiasis. Nephrology (Saint-Petersburg) 2011;15(3):11–17. (In Russ.) https://doi.org/10.24884/1561-6274-2011-15-3-11-17
72. Bravi CA, Larcher A, Capitanio U et al. Perioperative outcomes of open, laparoscopic, and robotic partial nephrectomy: a prospective multicenter observational study (the RECORd 2 project). Eur Urol Focus 2021;7(2):390–396. https://doi.org/10.1016/j.euf.2019.10.013. Epub 2019 Nov 12. PMID: 31727523
73. Zhuo M, Yang D, Goldfarb-Rumyantzev A, Brown RS. The association of SBP with mortality in patients with stage 1–4 chronic kidney disease. J Hypertens 2021;39(11):2250–2257. doi: 10.1097/hjh.0000000000002927
74. Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360 2021;2(12):2027–2037. doi:10.34067/KID.0002772021
75. Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 2021;398(10296):262–276. doi: 10.1016/S0140-6736(21)00536-5
76. Bakris GL, Agarwal R, Anker SD et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383(23):2219–2229. doi: 10.1056/NEJMOA2025845
77. Portolés J, Martín L, Broseta JJ, Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front Med (Lausanne) 2021;8:642296. doi: 10.3389/FMED.2021.642296
78. Babitt JL, Eisenga MF, Haase VH et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int 2021;99(6):1280–1295. doi: 10.1016/J.KINT.2021.03.020
79. Wish JB. Treatment of anemia in kidney disease: beyond erythropoietin. Kidney Int Rep 2021;6(10):2540–2553. doi: 10.1016/J.EKIR.2021.05.028
80. Hahn D, Hodson EM, Fouque D. Low protein diets for nondiabetic adults with chronic kidney disease. Cochrane Database Syst Rev 2020;10(10):CD001892. doi: 10.1002/14651858.CD001892.pub5
81. Molina P, Gavela E, Vizcaíno B, Huarte E, Carrero JJ. Optimizing diet to slow CKD progression. Front Med (Lausanne) 2021;8:654250. doi: 10.3389/FMED.2021.654250
82. Mills KT, Chen J, Yang W, et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016;315(20):2200–2210. doi: 10.1001/jama.2016.4447
83. Raphael KL. Metabolic acidosis in CKD: core curriculum 2019. Am J Kidney Dis 2019;74(2):263–275. doi: 10.1053/J.AJKD.2019.01.036
84. Madias NE. Metabolic acidosis and CKD progression. Clin J Am Soc Nephrol 2021;16(2):310–312. doi: 10.2215/CJN.07990520
Review
For citations:
Popov S.V., Huseynov R.H., Sivak K.V., Lelyavina T.A., Bunenkov N.S., Beshtoev A.H. The possibility of surgical treatment of urolithiasis in patients with chronic kidney disease. Nephrology (Saint-Petersburg). 2025;29(1):35-45. (In Russ.) https://doi.org/10.36485/1561-6274-2025-29-1-35-45. EDN: APELNU
Views:
184
Email this article 